Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Radiotherapy

10 evidence topics · 8 sources

EORTC 62991-22998 multicenter prospective phase II trial: local control and response

“To determine the activity of radiotherapy in patients with inoperable desmoid-type fibromatosis (DF) a multicenter prospective phase II trial was carried out.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“(EORTC 62991-22998)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Patients with inoperable progressive disease of primary, recurrent or incompletely resected lesions received a dose of 56 Gy in 28 fractions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Forty-four patients (27 F/17 M) were enrolled from 2001 to 2008. Median age was 39.5 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Median follow-up was 4.8 years. The 3-year local control rate was 81.5% (90% one-sided confidence interval 74% to 100%). Best overall response during the first 3 years was complete response (CR) 6 (13.6%), partial response (PR) 16 (36.4%), stable disease 18 (40.9%), progressive disease 3 (6.8%) and nonassessable 1 (2.3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Response after radiation therapy is slow with continuing regression seen even after 3 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote